Desuden konkluderede CHMP, at der er brug for flere oplysninger for bedre at få belyst den langsigtede sikkerhed af Protopy hvad angår sammenhængen med ondartede lidelser.
In addition, the CHMP concluded that further data are required to better elicit the long-term safety of Protopy in respect of its association with malignancies.